FrancophonIA/ELRC3.0 huggingface dataset:
English: Pioglitazone ratiopharm GmbH was also to be used together with insulin in patients who are not satisfactorily controlled with insulin alone and cannot take metformin.
Estonian: Ravimit Pioglitazone ratiopharm GmbH kavatseti kasutada ka koos insuliiniga patsientidel, kellele üksnes insuliini manustamine ei mõju rahuldavalt ja kes ei saa kasutada metformiini.
English: Pioglitazone ratiopharm GmbH was also to be used in combination with metformin in patients who are not satisfactorily controlled on metformin alone.
Estonian: Ravimit Pioglitazone ratiopharm GmbH kavatseti kasutada ka koos metformiiniga patsientidel, kelle haigus ainult metformiini kasutamisel rahuldavalt ravile ei allu.
English: Pioglitazone ratiopharm GmbH was to be used to treat type 2 diabetes in adults, particularly those who are overweight.
Estonian: Ravimit Pioglitazone ratiopharm GmbH kavatseti kasutada eelkõige ülekaaluliste täiskasvanud patsientide II tüüpi diabeedi raviks Seda kavatseti kasutada koos dieedi ja füüsilise koormusega.
English: Pioglitazone ratiopharm GmbH was to be used on its own in patients for whom metformin (another antidiabetes medicine) is not suitable.
Estonian: Ravimit Pioglitazone ratiopharm GmbH kavatseti kasutada ainsa ravimina patsientidel, kellele ei sobi metformiin (samuti diabeediravim).
English: What was Pioglitazone ratiopharm GmbH expected to be used for?
Estonian: Milline on ravimi Pioglitazone ratiopharm GmbH eeldatav toime?
English: The final opinion was sent to the European Commission, which issued a legally binding decision on 19 November 2014.
Estonian: Lõplik arvamus saadeti Euroopa Komisjonile, kes võttis 19. novembril 2014 vastu õiguslikult siduva otsuse.
English: Contact our press officers Monika Benstetter or Martin Harvey
Estonian: Monika Benstetter või Martin Harvey
English: Since 2013 MACI has been marketed in Denmark, Greece and the UK.
Estonian: Alates 2013. aastast on ravimit MACI turustatud Taanis, Kreekas ja Ühendkuningriigis.
English: Consequently, the licence of the manufacturing site was withdrawn.
Estonian: Seejärel võeti tagasi tootmiskoha litsents.
English: The safety and effectiveness of the product has not changed.
Estonian: Ravimi ohutus ja efektiivsus ei ole
English: MACI was on the market since 1998 in individual EU countries according to national procedures.
Estonian: Alates 1998. aastast turustati ravimit MACI üksikutes Euroopa Liidu liikmesriikides riiklike menetluste kohaselt.
English: More about the closure of the manufacturing site
Estonian: Lisateave tootmiskoha sulgemise kohta
English: Following the closure of the manufacturing site and because EU legislation1 requires authorised medicines to have a registered manufacturing site, a review was initiated at the request of the European Commission on 10 September 2014 (under Article 20 of Regulation (EC) No 726/2004) to determine whether the marketing authorisation for MACI should be suspended or revoked.
Estonian: Pärast tootmiskoha sulgemist ja kuna Euroopa Liidu õigusaktides1 nõutakse, et heakskiidetud ravimitel oleks registreeritud tootmiskoht, algatati Euroopa Komisjoni nõudmisel 10. septembril 2014 (määruse (EÜ) nr 726/2004 artikli 20 alusel) läbivaatamine, et teha kindlaks, kas MACI müügiluba tuleks peatada või tühistada.
English: Arrangements in place for existing patients to complete their treatment
Estonian: Praeguste patsientide ravi lõpetamise kord
English: In addition, surgeons were asked not to start new patients on MACI.
Estonian: Lisaks paluti kirurgidel mitte alustada uute patsientide
English: A letter was sent to healthcare professionals informing them of the site closure and requesting that they notify the marketing authorisation holder of those patients who wish to complete their treatment.
Estonian: Tervishoiuspetsialistidele saadeti kiri, milles neid teavitati tootmiskoha sulgemisest ja paluti, et nad teavitaksid müügiloa hoidjat patsientidest, kes soovivad oma ravi lõpuni viia.
English: Because MACI is an advanced therapy medicine, the review was carried out by the Committee on Advanced Therapies (CAT), and was subsequently endorsed by the Committee for Medicinal Products for Human Use (CHMP), which is responsible for questions concerning medicines for human use.
Estonian: Et MACI on uudne ravim, siis teostas läbivaatuse uudsete ravimeetodite komitee ja seda toetas seejärel inimravimite komitee, kes vastutab inimravimeid puudutavate küsimuste eest.
English: It was subsequently evaluated through the European Medicines Agency to comply with the EU regulation on advanced therapies, which requires all advanced therapies in EU Member States to undergo an evaluation by the Agency in order to obtain an EU-wide marketing authorisation; this was obtained in 2013.
Estonian: Seejärel hinnati seda Euroopa Ravimiameti kaudu, et see vastaks uudseid ravimeid käsitlevale Euroopa Liidu määrusele, mille kohaselt peab kõiki Euroopa Liidu liikmesriikide uudseid ravimeid kogu Euroopa Liitu hõlmava müügiloa saamiseks hindama Euroopa Ravimiamet; luba saadi 2013. aastal.
English: The European Medicines Agency has been working with the marketing authorisation holder since June 2014 to ensure that patients who had already started the treatment procedure were able to complete their treatment.
Estonian: Alates 2014. aasta juunist on Euroopa Ravimiamet teinud müügiloa hoidjaga koostööd, et tagada raviprotseduuride lõpetamine ravi juba alustanud patsientidel.
English: MACI is an implant used to repair cartilage defects at the ends of the bones of the knee joint.
Estonian: MACI on implantaat, millega parandatakse põlveliigese luude otste kõhrkoe kahjustusi.
English: • New patients should be treated with a suitable alternative and surgeons should not order new
Estonian: • Uusi patsiente tuleb ravida sobiva alternatiiviga ja kirurgid ei tohi tellida MACI jaoks uusi biopsiakomplekte.
English: 19 November 2014
Estonian: 19. november 2014 EMA/733307/2014
English: Closure of EU manufacturing site for MACI
Estonian: MACI tootmiskoha sulgemine Euroopa Liidus
English: • The closure was due to commercial reasons and is not related to any change in the safety and
Estonian: • Tootmiskoht suleti ärilistel põhjustel ning see ei ole seotud muutustega MACI ohutuses ega efektiivsuses.
English: • Surgeons and hospitals that have been using MACI were informed in June 2014 of the planned closure of the EU manufacturing site for MACI.
Estonian: • 2014. aasta juunis teavitati ravimit MACI kasutanud kirurge ja haiglaid MACI tootmiskoha kavandatud sulgemisest Euroopa Liidus.
English: Based on the draft opinion adopted by the CAT, the CHMP adopted a final opinion on 25 September 2014, recommending the suspension of the marketing authorisation for MACI until a new manufacturing site is registered in the EU.
Estonian: Uudsete ravimeetodite komitee vastuvõetud arvamuse projekti põhjal võttis inimravimite komitee 25. septembril 2014 vastu lõpliku arvamuse, milles soovitas peatada MACI müügiloa kuni uue tootmiskoha registreerimiseni Euroopa Liidus.
English: On 5 September 2014, the marketing authorisation holder for the advanced therapy medicine MACI (matrix applied characterised autologous cultured chondrocytes) closed the EU manufacturing site for the medicine, which is located in Denmark.
Estonian: 5. septembril 2014 sulges uudse ravimi MACI (maatriksile kantud kirjeldatud omadustega autoloogsed kasvatatud kondrotsüüdid) müügiloa hoidja ravimi Euroopa Liidu tootmiskoha Taanis.
English: The closure was due to commercial reasons and the safety and effectiveness of
Estonian: Tootmiskoht suleti ärilistel põhjustel ning MACI ohutus ja
English: Following the closure of the site, the marketing authorisation holder has been requested to store any remaining biopsies that have not yet been used to allow for potential later treatment with MACI, unless patients and their treating surgeons have explicitly indicated that they do not wish to complete
Estonian: Tootmiskoha sulgemise järel paluti müügiloa hoidjal säilitada kõik allesolevad kasutamata biopsiad, et võimaldada hilisemat potentsiaalset ravi ravimiga MACI, v.a kui patsiendid ja nende kirurgid on selge sõnaga teatanud, et ei soovi ravi ravimiga MACI lõpuni viia.
English: • The EU manufacturing site for MACI has been closed for commercial reasons and the product will remain unavailable for new patients in the EU until a new manufacturing site has been registered.
Estonian: • MACI tootmiskoht Euroopa Liidus suleti ärilistel põhjustel ning ravimit ei turustata Euroopa Liidus uutele patsientidele kuni uue tootmiskoha registreerimiseni.
English: • Patients who have already started treatment (i.e. those who have had their biopsies taken) should have been informed about the closure and should have discussed arrangements for completion of treatment with their treating surgeon.
Estonian: • Ravi juba alustanud patsientidele (st kellelt on võetud biopsia) peab tootmiskoha sulgemisest teatama ja neid raviv kirurg peab nendega arutama ravi lõpuleviimise korda.
English: • For patients who have already started treatment (i.e. those who have had their biopsies taken) company has made arrangements to store any existing biopsies so that treatment can be completed unless patients and their treating surgeons have explicitly indicated that they no longer wish to complete treatment with MACI.
Estonian: • Ravi juba alustanud patsientide jaoks (st kellelt on võetud biopsia) on ettevõte teinud ettevalmistusi allesolevate biopsiate säilitamiseks, et ravi saaks lõpetada, v.a juhul, kui patsiendid ja nende kirurgid on selge sõnaga teatanud, et ei soovi enam ravi ravimiga MACI lõpuni viia.
English: MACI is an advanced therapy medicinal product called a ‘tissue engineered product'.
Estonian: MACI on koetehnoloogiatoodete hulka kuuluv uudne ravim.
English: MACI is unavailable for new patients in the EU until a new manufacturing site has been registered in the EU.
Estonian: Euroopa Liidus ei turustata ravimit MACI uutele patsientidele kuni uue Euroopa Liidu tootmiskoha registreerimiseni.
English: The site has now been closed and MACI remains unavailable for new patients in the EU until a new manufacturing site has been registered in the EU.
Estonian: Tootmiskoht on nüüdseks suletud ning ravimit MACI ei turustata Euroopa Liidus uutele patsientidele kuni uue tootmiskoha registreerimiseni Euroopa Liidus.
English: • The company has made arrangements to store any existing biopsies so that treatment can be completed unless patients and their treating surgeons explicitly indicated that they no longer wish
Estonian: • Ettevõte on teinud ettevalmistusi allesolevate biopsiate säilitamiseks, et ravi saaks lõpetada, v.a juhul, kui patsiendid ja nende kirurgid on selge sõnaga teatanud, et ei soovi ravi ravimiga MACI
English: The elimination half-life was approximately two hours.
Estonian: Eliminatsiooni poolväärtusaeg oli ligikaudu kaks tundi.
English: IntronA with food and drink and alcohol
Estonian: IntronA koos toidu, joogi ja alkoholiga
English: There are no data on long term effects on sexual maturation.
Estonian: Puuduvad andmed pikaajalise toime kohta seksuaalsele küpsemisele.
English: Other medicines and IntronA
Estonian: Muud ravimid ja IntronA
English: Not all dose forms and strengths are appropriate for some indications.
Estonian: Mitte kõik ravimvormid ning tugevused ei ole teatud näidustuste korral sobilikud.
English: IntronA is usually intended for subcutaneous use.
Estonian: IntronA on tavaliselt mõeldud subkutaanseks kasutamiseks.
English: Do not use this medicine if you notice changes in the appearance of IntronA.
Estonian: Ärge kasutage seda ravimit, kui täheldate muutusi IntronA välimuses.
English: Overall Response a (n=118)
Estonian: Üldine ravivastus a (n = 118)
English: Laboratory Tests
Estonian: Laboratoorsed testid
English: Please make sure to select an appropriate dose form and strength.
Estonian: Palun veenduge, et olete valinud sobiva ravimvormi ning tugevuse.
English: This regimen must be maintained unless the disease progresses rapidly or severe intolerance is manifested.
Estonian: Niisugust režiimi tuleb säilitada, välja arvatud haiguse järsu progressiooni või tugeva talumatuse ilmnemisel.
English: Check with your doctor immediately if you have any of these symptoms.
Estonian: Konsulteerige otsekohe arstiga, kui märkate mõnda nendest sümptomitest.
English: Long-Term efficacy data
Estonian: Pikaajalise efektiivsuse andmed
English: IntronA can be put back in the refrigerator at any time during this seven-day period.
Estonian: IntronA võib selle 7-päevase perioodi jooksul igal ajal külmkappi tagasi panna.
English: Your doctor will determine the exact dosage schedule and regimen according to your needs.
Estonian: Teie arst määrab kindlaks täpse annustamisskeemi ja -režiimi vastavalt teie vajadustele.
English: The decision to treat should be made on a case by case basis (see section 4.4).
Estonian: Otsus ravi alustamiseks tuleb teha igal juhtumil eraldi (vt lõik 4.4).
English: If the medicine is not used during the seven-day period, it should be discarded.
Estonian: Kui ravimit 7-päevase perioodi jooksul ära ei kasutata, tuleb see hävitada.
English: • Genotype 2/3: The recommended duration of treatment is 24 weeks.
Estonian: • Genotüüp 2/3: soovitatav ravikuuri pikkus on 24 nädalat.
English: Store in a refrigerator (2°C - 8°C).
Estonian: Hoida külmkapis (2 C...8 C).
English: What IntronA contains
Estonian: Mida IntronA sisaldab
English: If you have them, you may have had a serious allergic reaction to IntronA.
Estonian: Kui need teil esinevad, võib teil olla tekkinud raske allergiline reaktsioon IntronA-le.
English: The infusion must be prepared immediately prior to use.
Estonian: Infusioonilahus tuleb ette valmistada vahetult enne kasutamist.
English: If you have the impression that the effect of IntronA is too strong or too weak, talk to your doctor or pharmacist.
Estonian: Kui teile jääb mulje, et IntronA toime on liiga tugev või liiga nõrk, konsulteerige oma arsti või apteekriga.
English: • Genotype 1: The recommended duration of treatment is one year.
Estonian: • Genotüüp 1: soovitatav ravikuuri pikkus on 1 aasta.
English: *Number (%) of patients
Estonian: * Patsientide arv (%).
English: IntronA is given either daily (5 or 7 times a week), or three times a week, every other day, for example on Monday, Wednesday, and Friday.
Estonian: IntronA manustatakse kas iga päev (5 kuni 7 korda nädalas) või kolm korda nädalas igal teisel päeval, näiteks esmaspäeval, kolmapäeval ja reedel.
English: Some children did not reach their projected height within 10-12 years after completing treatment.
Estonian: Mõned lapsed ei saavutanud oma oodatavat kehapikkust 10...12 aasta jooksul pärast ravi lõpetamist.
English: Do not attempt to inject yourself unless you are sure you understand the procedure and requirement of self-injection.
Estonian: Ärge proovige ise süstida, kui te pole veendunud, et olete aru saanud iseseisva süstimise protseduurist ja nõuetest.
English: Ribavirin causes serious birth defects when administered during pregnancy.
Estonian: Ribaviriin põhjustab raseduse ajal manustatuna tõsiseid väärarenguid.
English: Laguno M, Murillas J, Blanco J.L et al. AIDS 2004; 18(13): F27-F36.
Estonian: Laguno M., Murillas J., Blanco J.L. jt. AIDS 2004; 18(13): F27-F36.
English: Date of first authorisation: 9 March 2000 Date of latest renewal: 9 March 2010
Estonian: Müügiloa esmase väljastamise kuupäev: 09/03/2000 Müügiloa viimase uuendamise kuupäev: 09/03/2010
English: For storage conditions of the medicinal product, see section 6.3.
Estonian: Ravimpreparaadi säilitamistingimusi vt lõik 6.3.
English: Growth and development (children and adolescents):
Estonian: Kasvamine ja areng (lapsed ja noorukid)
English: Table 6 Sustained virological response rates (n a,b
Estonian: Tabel 6 Püsiv viroloogiline ravivastus (n a,b
English: Clinical experience indicates that a haematological and cytogenetic major/minor response is obtainable in the majority of patients treated.
Estonian: Kliiniline kogemus näitab, et hematoloogiline ja tsütogeneetiline tugev/nõrk ravivastus saavutatakse enamikul ravitavatest patsientidest.
English: Your doctor or his/her assistant will instruct you how to selfinject IntronA.
Estonian: Teie arst või tema abiline juhendab teid, kuidas IntronA-d iseseisvalt süstida.
English: Your doctor has prescribed IntronA specifically for you and your current condition; do not share this medicine with anyone else.
Estonian: Teie arst on määranud IntronA ravi teile ainuisikuliselt ja konkreetse seisundi raviks; ärge andke seda ravimit kellelegi teisele.
English: If you forget to use IntronA
Estonian: Kui te unustate IntronA-d kasutada
English: During treatment for hepatitis B or C the recommended testing schedule is at weeks 1, 2, 4, 8, 12, 16, and every other month, thereafter, throughout treatment.
Estonian: B- või C-hepatiidi ravi korral on soovitatav teostada testid 1., 2., 4., 8., 12., 16. nädalal pärast ravi algust ning seejärel igal teisel ravikuul.
English: The usual starting dose for each condition follows; however, individual doses may vary, and the doctor may change your dose based on your specific needs:
Estonian: Järgnevalt on toodud iga seisundi korral kasutatavad algannused; sellele vaatamata võivad individuaalsed annused erineda ja teie arst võib annust muuta teie individuaalsusest lähtuvalt:
English: The clear and colourless solution is contained in a glass vial.
Estonian: Selge ja värvitu lahus paikneb klaasviaalis.
English: If you use more IntronA than you should Contact your doctor or healthcare professional as soon as possible.
Estonian: Kui te kasutate IntronA-d rohkem kui ette nähtud Võtke ühendust oma arsti või tervishoiuspetsialistiga niipea kui võimalik.
English: The mechanism behind these events is not known (see sections 4.3, 4.4 and 4.5 of the telbivudine SPC).
Estonian: Nende juhtude tekke mehhanism on teadmata (vt lõigud 4.3, 4.4 ja 4.5 telbivudiini ravimi omaduste kokkuvõttest).
English: Examine the solution prior to administration: it should be clear and colourless.
Estonian: Kontrollige lahustatud ravimit enne kasutamist: see peab olema selge ja värvitu.
English: Authorized Representative: BD, Laagstraat 57, B-9140 Temse, Belgium
Estonian: BD, Laagstraat 57, B-9140 Temse, Belgia
English: Very rarely: Not known:
Estonian: Väga harv: Teadmata:
English: Preparation of IntronA for intravenous infusion: The infusion is to be prepared immediately prior to use.
Estonian: IntronA ettevalmistamine intravenoosseks infusiooniks: infusioonilahus tuleb ette valmistada vahetult enne kasutamist.
English: IntronA is to be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
Estonian: IntronA-d tuleb raseduse ajal kasutada ainult juhtudel, kui oodatav kasu õigustab võimalikku riski lootele.
English: Patients with advanced disease may require a daily dose of 5 million IU.
Estonian: Kaugelearenenud haigusega patsiendid võivad vajada päevast annust 5 miljonit RÜ.
English: *AUC12 (ng.hr/mL) for ribavirin; AUC0-24 (IU.hr/mL) for IntronA
Estonian: * AUC12 (ng•t/ml) ribaviriini; AUC0-24 (RÜ•t/ml) IntronA jaoks
English: The pharmacokinetics of IntronA and ribavirin (dose-normalized) are similar in adults and children or adolescents.
Estonian: IntronA ja ribaviriini (normannuses) farmakokineetika on täiskasvanutel ja lastel või noorukitel sarnane.
English: Pyrexia and fatigue were often reversible within 72 hours of interruption or cessation of treatment.
Estonian: Püreksia ja väsimus olid sageli pöörduvad 72 tunni jooksul pärast ravi katkestamist või lõpetamist.
English: Study results are summarized in Table 5.
Estonian: Uuringu tulemused on kokku võetud tabelis 5.
English: Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Estonian: Teatage oma arstile või apteekrile, kui te kasutate või olete hiljuti kasutanud mis tahes muid ravimeid, kaasa arvatud ilma retseptita ostetud ravimeid.
English: Peripheral neuropathy
Estonian: Perifeerne neuropaatia.
English: What you need to know before you use IntronA
Estonian: Mida on vaja teada enne IntronA kasutamist
English: A five-year long-term, observational, follow-up study enrolled 97 paediatric chronic hepatitis C patients after treatment in the standard interferon multicentre trials.
Estonian: Viieaastane pikaajaline vaatlev jätku-uuring hõlmas 97 kroonilise C-hepatiidiga pediaatrilist patsienti pärast ravi standardse interferooniga mitmekeskuselistes uuringutes.
English: Therefore, the combination of IntronA with telbivudine is contraindicated (see section 4.3).
Estonian: Seetõttu on IntronA kombinatsioon telbivudiiniga vastunäidustatud (vt lõik 4.3).
English: b: n = number of responders/number of subjects with given genotype, and assigned treatment duration.
Estonian: b: n = ravivastuse saavutanud/antud genotüübiga isikute arv ja määratud ravi kestus.
English: MIU = million international units; TIW = three times a week.
Estonian: RÜ = rahvusvaheline ühik, TIW = kolm korda nädalas.
English: Contact your doctor or pharmacist if needed.
Estonian: Vajadusel võtke ühendust oma arsti või apteekriga.
English: Patients with psoriasis and sarcoidosis
Estonian: Psoriaasi ja sarkoidoosiga patsiendid
English: Intravenous infusion:
Estonian: Veenisisene infusioon:
English: Suicide, suicide attempts, aggressive behaviour (sometimes directed against others), psychosis including hallucinations
Estonian: Suitsiid, enesetapukatsed, agressiivne käitumine (mõnikord suunatud teiste inimeste vastu), psühhoos, sealhulgas hallutsinatsioonid.
English: The study results are summarized in Table 6.
Estonian: Uuringu tulemused on kokku võetud tabelis 6.
English: Hypertension Peripheral ischaemia, hypotension
Estonian: Perifeerne isheemia, hüpotensioon
English: What IntronA is and what it is used for
Estonian: Mis ravim on IntronA ja milleks seda kasutatakse
English: No studies have been conducted in juvenile animals to examine the effects of treatment with interferon alfa-2b on growth, development, sexual maturation, and behaviour.
Estonian: Noorloomadega ei ole tehtud katseid, et uurida alfa-2b-interferooni ravi mõju kasvule, arengule, seksuaalsele küpsemisele ja käitumisele.
English: What IntronA looks like and contents of the pack
Estonian: Kuidas IntronA välja näeb ja pakendi sisu
English: M-cresol
Estonian: M-kresool
English: Moreover children treated with interferon alfa-2b experienced a reduced rate of growth and some cases of depression were observed.
Estonian: Lisaks esines alfa-2b-interferooniga ravitud lastel kasvukiiruse langus ja mõningatel juhtudel täheldati depressiooni.
English: Genotype 2/3/4 (n=26)
Estonian: Genotüüp 1 (n = 92) Genotüüp 2/3/4 (n = 26)
English: The interferons are a family of small protein molecules with molecular weights of approximately 15,000 to 21,000 daltons.
Estonian: Interferoonid on väikeste proteiinide perekond molekulmassiga vahemikus 15 000…21 000 daltonit.
English: Be sure to seek emergency care if you notice that you are becoming depressed or have suicidal thoughts or change in your behaviour.
Estonian: Kutsuge kindlasti kiirabi, kui täheldate, et olete depressioonis, teil on enesetapu mõtted või kui teie käitumine on muutunud.
English: 462 patients completed at least 5 years of long-term follow-up and only 12 sustained responders' out of 492 relapsed during this study.
Estonian: 462 patsienti lõpetasid vähemalt 5 aastat kestnud pikaajalise jälgimisperioodi ning ainult 12-l püsiva ravivastusega patsiendil 492-st esines retsidiiv.
English: Auto-antibodies and autoimmune disorders
Estonian: Autoantikehad ja autoimmuunsed häired
English: Moderate and usually reversible pancytopenia has been reported.
Estonian: Teatatud on mõõdukast ja tavaliselt pöörduvast pantsütopeeniast.
English: If you take telbivudine with a pegylated interferon alfa-2a or any type of injectable interferon product, your risk of developing peripheral neuropathy (numbness, tingling and/or burning sensations in the arms and/or legs) is higher.
Estonian: Kui te võtate telbivudiini koos pegüleeritud alfa-2a-interferooniga või ükskõik millise süstitava interferooniga, siis on teie risk perifeerse neuropaatia (tuimus, surisemine ja/või põletuse aistingud kätes ja/või jalgades) tekkeks kõrgem.